Form 4: Summit Therapeutics Co-CEO Acquires Shares in Private Placement

Co-CEO Mahkam Zanganeh acquires 44,052 shares of Summit Therapeutics in a private placement at $22.70 per share.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer of Summit Therapeutics Inc., acquired 44,052 shares of common stock through a private placement.
• The transaction occurred on September 11, 2024, and closed on September 13, 2024.
• The shares were purchased at a price of $22.70 per share.
• The acquisition was made by the Mahkam Zanganeh Revocable Trust, with Mahkam Zanganeh as Trustee.
• Following the transaction, Zanganeh beneficially owns 520,814 shares directly and has indirect ownership through various trusts and family members.
• Zanganeh disclaims beneficial ownership of shares held by the Shaun Zanganeh Irrevocable Trust and shares held by an immediate family member, except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the Co-CEO's purchase indicates confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• The Co-CEO's investment in the company may signal confidence in its future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by a top executive is often seen as a positive sign.

Stakeholder Impact

• The transaction could positively influence shareholder sentiment.

Key Dates